Are SERDs dead? 'Good question,' says Sanofi R&D chief, after French pharma's late-stage pipeline takes a beating.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      SANOFI SA
    • Subject Terms:
      REED, Jack, 1949-
    • Abstract:
      Was the problem with amcenestrant, or are SERDs another dead end for cancer drug development? "It's a good question," says John Reed. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of FierceBiotech is the property of Questex Media Group and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)